Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + carboplatin every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer
NL-OMON28184Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2000
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Started Jun 2000; status: active, not recruiting.
02
Drugs
docetaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON28184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28184.